AbstractBySubCategory

Prostate Cancer - Localized Disease

Genitourinary Cancer

2017 Genitourinary Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci. Rosalind Eeles

01

Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. L. Michael Glode

02

Luminal and basal subtyping of prostate cancer. Felix Yi-Chung Feng

03

Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens. Paul L. Nguyen

04

Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era. Amar Upadhyaya Kishan

07

Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy. Shree Agrawal

09

Frequency of DNA repair gene mutations in localized and metastatic prostate cancer. Marc Dall'Era

10

The effect of prostatectomy technique on genitourinary toxicity. Jay P. Ciezki

100

Implications of prostate cancer with diabetes mellitus on patient outcomes and care: A matched case-control study. Nina J. Karlin

101

Autophagic cell death with hydroxychloroquine in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. Mridula Annette George

102

Baseline differences in characteristics of a racially diverse group of men electing active surveillance. Allison H. Feibus

103

National survey of practice patterns employing MRI-guided prostate biopsy for diagnosis of prostate cancer. Graham Tooker

104

Defining the index lesion for salvage partial gland ablation after radiation therapy for localized prostate cancer. Arjun Sivaraman

105

Long-term aspirin use and intratumoral gene expression in prostate cancer. Konrad Hermann Stopsack

106

Satisfying the fatty acid demand of prostate cancer: De novo synthesis versus uptake as alternative and potentially cooperative prostate cancer phenotypes. Sandra Marlene Gaston

107

A circulating miRNA signature to help prognosticate at prostate cancer diagnosis. Ailsa Roberg Sita-Lumsden

108

Application of stable isotopic tracing in an ex-vivo system to reveal heterogeneous patterns of androgen metabolism in localized, hormone-naïve prostate cancer. Charles Dai

109

A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment. Suneil Jain

11

Characterization of circulating tumor cells in patients with localized high risk prostate cancer, post-prostatectomy. Terence W. Friedlander

110

Feasibility of robot-assisted radical prostatectomy in elderly patients: Comparative analysis of the perisurgical/oncological outcomes with younger patients. Noriyoshi Miura

111

Informed decision making (IDM) for prostate cancer (PCa) screening in a high-risk population. Puneet Dhillon

112

Defining predictors of early, intermediate, and late biochemical recurrence in men with clinically localized prostate cancer treated with minimally invasive radical prostatectomy. Silvia Garcia Barreras

113

The impact of Gleason pattern 4 ratio on recurrence following radical prostatectomy in Japanese patients with prostate cancer. Masashi Kato

114

Racial variation in the reliability of prostate cancer indicators in men undergoing subsequent prostate biopsy. Robert Scott Libby

115

Predicting late fecal incontinence risk after RT for prostate cancer: External independent validation. Alessandro Cicchetti

116

Comparison of biochemical recurrence-free survival after radical prostatectomy among men in active surveillance following grade reclassification and men newly diagnosed with similar grade disease. Clarissa P. Diniz

117

Predictors for reclassification at repeat biopsy in active surveillance cohort for low-risk prostate cancer: From an interim analysis of PRIAS-JAPAN. Mikio Sugimoto

118

The impact of pretreatment MRI on genitourinary and gastrointestinal toxicity after radiation therapy in patients with localized prostate cancer. Kyle Kilinski

119

Nationwide analysis: Changes in the natural history of low risk localized prostate cancer. Helgstrand Thomas John

12

Early toxicity in a prospective phase I/II trial of MRI-assisted focal boost integrated with HDR monotherapy for low- and intermediate-risk prostate cancer. Laura D'alimonte

120

Factors affecting the risk of erroneous interpretation of online surgeon rating websites among the general population. Christopher J. Weight

121

Multimodal image and mapping guided focal salvage high-dose-rate brachytherapy for local recurrent prostate cancer. Stephane Gilles Guerif

122

Prostate specific antigen five years following stereotactic body radiation therapy (SBRT) for low and intermediate risk prostate cancer: An ablative procedure? Shaan Kataria

123

Results from a phase II trial (NTC01902680) of ultrafocal brachytherapy for low/intermediate risk prostate cancer. Pierre Graff-Cailleaud

124

Effect of heparin bridged transrectal prostate biopsy on the risk of hemorrhage in patients requiring temporary discontinuation of warfarin. Itsuto Hamano

125

Health-related quality of life outcomes in a phase I/II study of stereotactic hypofractionated once-weekly radiation therapy (SHORT) for nonmetastatic prostate cancer. Indranil Mallick

126

Development of a screening tool to assess prostate cancer health literacy. Ashwin A. Kotwal

127

Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients undergoing prostate biopsy in a prospective data register. Aksam Yassin

128

A combination of both testosterone and white blood count as predictive factors of overall survival in localized prostate cancer. Daniel Taussky

129

The CHAPPP study: Changing care with PSMA-PET for prostate cancer—A retrospective study of the role of PSMA imaging in altering treatment pathways. Andrew Schmidt

13

Phase I/II study on stereotactic hypofractionated once-weekly radiation therapy (SHORT) for localized prostate cancer. Indranil Mallick

130

Impact of proximity to NCI- and NCCN-designated cancer centers on outcomes for patients with prostate cancer undergoing radical prostatectomy. Cameron Ghaffary

14

Changes in prostate cancer detection rate of fusion versus systematic biopsy over time: A single center experience. Brian P. Calio

15

The acute toxicity results of the GETUG-AFU 22 study: A multicenter randomized phase II trial comparing the efficacy of a short hormone therapy in combination with radiotherapy to radiotherapy alone as a salvage treatment for patients with detectable PSA after radical prostatectomy. Stephane Gilles Guerif

16

Impact of the primary information source used for decision making and implications for treatment regret in prostate cancer. Narek Shaverdian

17

Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Brandon Arvin Virgil Mahal

18

The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients. Kathryn T Dinh

19

IsoPSA: Interim clinical performance evaluation of a novel structure-based biomarker for prostate cancer in a multicenter prospective trial for Gleason ≥ 7. Eric A. Klein

20

A comparison of surrogate endpoints for all cause mortality in men with localized unfavorable-risk prostate cancer. Trevor Joseph Royce

21

The use of five-alpha reductase inhibitors and their association with reclassification and pathologic outcomes in the Canary Prostate Active Surveillance Study (PASS). James T Kearns

22

5-year patient-reported outcomes of bowel and urinary bother in the CHHiP trial (CRUK/06/016). David P. Dearnaley

23

Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study. John L. Gore

24

Cost-effectiveness analysis of magnetic resonance imaging-ultrasound fusion biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer. Matthew Ingham

25

Genomic architecture of radioresistant prostate cancer. Melvin Chua

26

Impact of use of phosphodiesterase type 5 inhibitors (PDE5-I) after radical prostatectomy (RP) on biochemical recurrence-free (BCRF) and overall survival (OS): A retrospective study from the Northwestern University SPORE in prostate cancer. Arden B. Roston

27

Temporal trends and factors associated with overuse of neoadjuvant androgen deprivation therapy in low and very low risk prostate cancer. John Oliver Delancey

28

The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Jamil Syed

29

Changes in multiparametric prostate MRI and immune subsets in patients (Pts) receiving neoadjuvant immunotherapy and androgen deprivation therapy (ADT) prior to radiation. Ravi Amrit Madan

30

A model for predicting focal ablation candidates in patients with prostate cancer based on MRI and biopsy criteria. Brian P. Calio

31

Can index lesion tumor volume on T2 weighted MRI predict biochemical recurrence following radical prostatectomy? Dordaneh Sugano

32

Prostate cancer in 671 hypogonadal men with and without long-term testosterone treatment: Results from a controlled registry study. Ahmad Haider

33

The impact of treatment delay from diagnosis to prostatectomy on the biochemical recurrence rate. Sudhir Isharwal

34

5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer. Donald B. Fuller

35

Prospective study of a 17-GENE RT-PCR-based assay for prediction of high risk pathology at radical prostatectomy. Neal D. Shore

36

Overall survival advantage with radical prostatectomy for prostate cancer. Christopher David Kosarek

37

Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues. Mohammed Alshalalfa

38

Difference in risk factors associated with biochemical recurrence after salvage RT compared to post-prostatectomy patients with negative margins. Austin B Hopper

39

Prostate cancer outcomes for African American and caucasian patients undergoing radical prostatectomy. Jennifer Cullen

40

Validation of a 17-Gene Genomic Prostate Score (GPS) as a predictor of biochemical recurrence (BCR) in men with prostate cancer treated with radical prostatectomy (RP) in a community setting. Stephen K. VanDenEeden

41

Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer. Ardalan Ahmad

42

Index lesion tumor volume on MRI to predict adverse pathologic outcomes following radical prostatectomy. Dordaneh Sugano

43

Improved imaging-pathology correlation with MR imaging-derived, 3D-printed, patient-specific whole-mount molds of the prostate. Daniel N. Costa

44

Combined abiraterone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. Stephane Supiot

45

Stereotactic body radiotherapy for high-risk prostate cancer (5 treatment days): Toxicity results of a phase II trial. Amar Upadhyaya Kishan

46

Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiotherapy. Sergio Faria

47

Toxicity, quality of life outcomes, and dosimetric impact in phase III trial of hypofractionated or standard fractionated proton therapy for low-risk prostate cancer patients: PCG GU 002. Matthew Q. Schmidt

48

Performance of a validated urine exosome gene expression assay to predict high-grade prostate cancer utilizing the International Society of Urological Pathology (ISUP) 2014 grading system. Michael Donovan

49

National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer. David Yang

50

Predicting disease progression in men with localized high risk prostate cancer undergoing radical prostatectomy. Yaw A. Nyame

51

The necessity of dynamic contrast enhanced imaging for prostate MRI: A study of pathologic outcomes on prostate biopsy. Sasha C. Druskin

52

Active surveillance: Do low-income patients adhere to the protocol? Ryan Kraus

53

Treatment patterns after the use of the 17-gene Genomic Prostate Score assay in Veterans newly diagnosed with clinically low-risk prostate cancer. Julie Ann Lynch

54

Conditional biochemical recurrence-free survival and cancer-specific mortality after radical prostatectomy at long term follow-up. Silvia Garcia Barreras

55

Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer. Michael Wang

56

Comparison of Gleason upgrading rates in transrectal ultrasound systematic random biopsies versus US-MRI fusion biopsies for prostate cancer. Arie Carneiro

57

Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer. Hao Gia Nguyen

58

Comparison of multiparametric MRI to PSA kinetics as an indication of prostate cancer progression in men on active surveillance. Mahir Maruf

59

Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes. Hima Bindu Musunuru

60

Does higher number of lymph nodes (LNs) excised during radical prostatectomy (RP) improve biochemical relapse-free survival (bRFS) in patients with pT2-3a/pN0 prostate cancer? Steven Neema Seyedin

61

Quality of life evaluation of the effect of decapeptyl compared with zoladex preradiotherapy: Final results of randomised controlled trial. Amit Bahl

62

Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer. Ayca Gucalp

63

A systematic review and meta-analysis to evaluate the influence of surgical method on specimen margins and biochemical recurrence after radical prostatectomy for high-risk prostate cancer. Victor Srougi

65

Permanent seed brachytherapy for low risk prostate cancer, long term outcome, and urinary toxicity. Hamid Raziee

66

A nomogram for testosterone recovery following combined androgen deprivation therapy and radiation therapy for prostate cancer. Daphna Spiegel

67

Impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or without androgen deprivation therapy for unfavorable-risk prostate cancer. Sagar Anil Patel

68

Evaluation of sexual function on a randomized trial of a prostate rectal spacer. Daniel A. Hamstra

69

Twitter mentions and academic citations in the urologic oncology literature. Solomon Hayon

70

Effect of dose to penile bulb (PB) on patient and clinician-reported erectile function (EF) in standard (SF) and hypofractionated (HF) prostate IGRT. Julia Murray

71

The diverse genomic landscape of low-risk prostate cancer. Matthew R. Cooperberg

72

Prediction of pathological outcome at radical prostatectomy for MRI-ultrasound fusion prostate biopsy versus standard transrectal ultrasound guided prostate biopsy. Hans Arora

73

Medications for urologic malignancies in the open payments data: Financial relationships between industry and urologists. Mahir Maruf

74

The importance of surgical margins for biochemical recurrence in high-risk prostate cancer patients. Victor Srougi

75

Can focal therapy impact perioperative, oncological, and functional outcomes in men who underwent focal therapy salvage robotic-assisted radical prostatectomy? A retrospective matched-pair comparative study. Igor Nunes-Silva

76

Localized prostate cancer and salvage treatment: EBRT first + salvage HIFU or HIFU first + salvage EBRT? A single-institution matched pair analysis over a 20-year period. Gilles Pasticier

77

Is there a relationship between testosterone levels at the end of short-term androgen deprivation therapy and outcomes in intermediate risk prostate cancer? Prospective data from a phase III trial. Abdenour Nabid

78

The IMPACT of 68GA-PSMA-PET in definitive radiotherapy planning for prostate cancer patients. Cem Onal

79

A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Neal D. Shore

80

EZH2 expression and clinical outcome in African-American men with prostate cancer. Vivek Narayan

81

Does a community cancer center one-day prostate cancer multidisciplinary clinic result in a change in treatment recommendation? Taylor Reid Cushman

82

Surgical center for ambulatory extended recovery: 30-day follow-up report of minimally invasive radical prostatectomy. Arjun Sivaraman

83

Screening for aggressive prostate cancer: A single-center experience using the 4Kscore and multiparametric MRI for the detection of Gleason 7 or higher prostate cancer. Vivek Venkatramani

84

Gender disparity: Overlooking hereditary prostate cancer. Lauren Bowling

85

Utilization of pelvic lymph node dissection for low-risk prostate cancer. Parth K. Modi

86

Risk prediction-modeling approach to identify best predictive parameters for urethral strictures after prostate brachytherapy. Sandeep Singhal

87

Genome-wide alterations in gene expression of prostate cancer (PC) cells surviving neoadjuvant androgen deprivation therapy (ADT). Anna C. Ferrari

88

Prospectively collected baseline erectile function (EF) in 1,173 consecutive newly diagnosed prostate cancer patients referred for radiotherapy. Jill Nicholson

89

Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy. Silvia Garcia Barreras

90

Influence of common comorbid conditions on a 17-gene assay for prediction of adverse pathology in clinically low-risk prostate cancer. Jennifer Cullen

91

Population based PSA screening in Mexico City. Jaime Omar Herrera-Caceres

92

OncotypeDx genomic scores independent of disease volume in men with favorable-risk prostate cancer. Dominic C. Grimberg

93

Management of high-risk prostate cancer with 5-treatment stereotactic body radiotherapy: Long-term results. Josephine Kang

94

Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer. Daniel Taussky

96

CANCAP02: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP). Simon Pacey

97

Genomic mechanisms of resistance to neoadjuvant leuprolide plus abiraterone in locally advanced prostate cancer. Adam G. Sowalsky

98

Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB). Jeanny B. Aragon-Ching

99

Outcomes of men who underwent treatment for prostate cancer from a prospective follow up of a racially diverse, multi-institutional active surveillance cohort. Nora M. Haney

e536

Focal cryo-hemiablation to treat unilateral localized prostate cancer: A prospective midterm oncologic and functional outcomes. Mohammed Baghdadi

e537

The impact of race on perceptions of anxiety after radical prostatectomy. Shilajit Kundu

e538

New frontiers ahead focal therapy postoperative follow-up: What is the real role of MRI in this setting? Igor Nunes-Silva

e539

Training and skills assessment for MRI/TRUS fusion-guided prostate biopsy: End-fire vs. side-fire ultrasound probes. Amit L Jain

e540

Focal therapy for prostate cancer: Attitude and practice patterns. Amit L Jain

e541

Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: A single-center study. Kazuhisa Hagiwara

e542

The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: A multi-institutional analysis. Takuya Koie

e543

A new technique of reporting prostate biopsy to predict prostatectomy outcome. Carl A. Olsson

e544

Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study. Brandon Arvin Virgil Mahal

e545

Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk? Gregory Auffenberg

e546

Utility of PCA3 and TMPRSS2: ERG urinary biomarkers to predict pathologic outcomes in African American men undergoing radical prostatectomy. Allison H. Feibus

e547

Racial variations in upgraded gleason scores of active surveillance candidates. Krishna Pandya

e548

Does shared decision making for PSA screening empower patients? James Austin Talcott

e549

The effect of androgen deprivation therapy on prostate cancer-specific mortality in high-risk prostate cancer: Patients treated with low dose-rate brachytherapy without supplementary external beam radiotherapy. Jay P. Ciezki

e550

Comparison of conventionally fractionated and hypofractionated schedule for post-prostatectomy salvage radiotherapy: Early results from non-randomized observational study. Jure Murgic

e551

Prostate cancer stage at diagnosis: First data from a Middle-Eastern cohort. Deborah Mukherji

e552

Aspirin use in robot-assisted radical prostatectomy? Systematic review and metanalysis. Arie Carneiro

e553

Permanent prostate brachytherapy and short-term androgen deprivation for favorable and unfavorable intermediate risk: Clinical results for median 5 year follow-up. Stephane Gilles Guerif

e554

Is multiparametric MRI able to characterize margin for focal brachytherapy in low-grade prostate cancer? Soleakhena Ken

e555

Assessment of discomfort and pain in patients undergoing fusion-MRI-guided versus TRUS-guided prostate biopsy. Dennis Robins

e556

Does the EPIC-26 measure five domains in English and Spanish speakers? Maria Carmen Mir

e557

Three year results of a prospective study on focal salvage HDR prostate brachytherapy for local recurrence after external beam radiotherapy (XRT). Hans T. Chung

e558

Angiomotin to regulate prostate cancer cell proliferation by signaling through Hippo-YAP pathway. Pengfei Shen

e559

Integrated somatic subtypes of localized intermediate-risk prostate cancer. Natalie S Fox

e560

Effect of incorporation of preoperative CT scan on bladder doses and irradiated volume in postprostatectomy radiation therapy (pPRT). Mani Akhtari

e561

Impact of castration resistant status on overall survival for prostate cancer patients treated with radical prostatectomy. Naoki Fujita

e562